Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

PREPAID EXPENSES AND OTHER CURRENT ASSETS

v3.25.1
PREPAID EXPENSES AND OTHER CURRENT ASSETS
 12 Months Ended
Dec. 31, 2024
Prepaid Expenses And Other Current Assets  
PREPAID EXPENSES AND OTHER CURRENT ASSETS

NOTE 6. PREPAID EXPENSES AND OTHER CURRENT ASSETS

 

The Company’s prepaid expenses and other current assets consist of the following:

 

    December 31, 2024     December 31, 2023  
Other receivables   £ 7,837     £ 51,584  
VAT owed to the Company     80,411       135,642  
Prepaid clinical trial costs     307,519       307,519  
Deferred clinical trial testing costs     1,177,500       1,177,500  
Deferred investor relations activity costs     1,523,206       -  
Deferred collaboration agreement costs     331,283       -  
Other prepayments     479,284       522,480  
Total prepaid expenses and other current assets   £ 3,907,040     £ 2,194,725  

 

The fair value of prepaid expenses and other current assets not materially different to the book value.